These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
323 related articles for article (PubMed ID: 35563772)
1. Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Maresca L; Stecca B; Carrassa L Cells; 2022 Apr; 11(9):. PubMed ID: 35563772 [TBL] [Abstract][Full Text] [Related]
2. Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. Carrassa L; Colombo I; Damia G; Bertoni F Cancer Treat Rev; 2020 Nov; 90():102090. PubMed ID: 32892059 [TBL] [Abstract][Full Text] [Related]
3. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach. Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747 [TBL] [Abstract][Full Text] [Related]
5. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Ngoi NYL; Westin SN; Yap TA Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597 [TBL] [Abstract][Full Text] [Related]
6. PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction Fröhlich LM; Niessner H; Sauer B; Kämereit S; Chatziioannou E; Riel S; Sinnberg T; Schittek B Cancer Res Commun; 2023 Sep; 3(9):1743-1755. PubMed ID: 37674529 [TBL] [Abstract][Full Text] [Related]
7. DNA damage response as a therapeutic target in gynecological cancers. Leary A; Auguste A; Mesnage S Curr Opin Oncol; 2016 Sep; 28(5):404-11. PubMed ID: 27455135 [TBL] [Abstract][Full Text] [Related]
8. Directing the use of DDR kinase inhibitors in cancer treatment. Brandsma I; Fleuren EDG; Williamson CT; Lord CJ Expert Opin Investig Drugs; 2017 Dec; 26(12):1341-1355. PubMed ID: 28984489 [TBL] [Abstract][Full Text] [Related]
9. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor. Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154 [TBL] [Abstract][Full Text] [Related]
10. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology. Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949 [TBL] [Abstract][Full Text] [Related]
11. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911 [TBL] [Abstract][Full Text] [Related]
12. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies. Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680 [TBL] [Abstract][Full Text] [Related]
13. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs. Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101 [TBL] [Abstract][Full Text] [Related]
14. The DNA Damaging Revolution: PARP Inhibitors and Beyond. Yap TA; Plummer R; Azad NS; Helleday T Am Soc Clin Oncol Educ Book; 2019 Jan; 39():185-195. PubMed ID: 31099635 [TBL] [Abstract][Full Text] [Related]
15. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition. Haynes B; Murai J; Lee JM Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007 [TBL] [Abstract][Full Text] [Related]
17. The synthetic lethality of targeting cell cycle checkpoints and PARPs in cancer treatment. Li S; Wang L; Wang Y; Zhang C; Hong Z; Han Z J Hematol Oncol; 2022 Oct; 15(1):147. PubMed ID: 36253861 [TBL] [Abstract][Full Text] [Related]
19. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides Voutsadakis IA; Stravodimou A Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505 [TBL] [Abstract][Full Text] [Related]
20. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors. Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]